Home > Research Areas > Cancer

Cancer

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC8331 GSK2256098 Featured GSK2256098 is small molecule FAK kinase inhibitor.
DC8491 GSK2879552 Featured GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
DC10647 EPZ015938(pemrametostat) Featured GSK3326595(EPZ015938) is the first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor.
DC2070 GSK690693 Featured GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively.
DC7812 GSK923295 Featured GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183.
DC10033 H3B-6527 Featured H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.
DC8768 HMN-214 Featured HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.
DC11262 IACS-010759 Featured IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain.
DC10174 Iberdomide Featured Iberdomide (CC-220) is a cereblon modulator in clinical development for systemic lupus erythematosis. Iberdomide exhibits an IC50 of 60 nM in TR-FRET cereblon binding assay.
DC11303 CT7001 hydrochloride Featured ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.
DC3130 ICG-001 Featured ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro
DC8111 Idarubicin Hydrochloride Featured Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor.
DC10538 IDH-305 Featured IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.
DC10098 IDO-IN-1 Featured IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM).
DC9014 Ifosfamide Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.
DC4181 Imatinib mesylate Featured Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
DC10406 Imisopasem manganese Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.
DC10918 INCB053914 INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively.
DC7167 Capmatinib(INCB28060) Featured INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase.
DC7429 INCB 8761 Featured INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist.
DC7171 INK-128(Sapanisertib) Featured INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.
DC5072 Duvelisib (IPI-145, INK1197) Featured IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.
DC9829 IPI-549 Featured IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma.
DC5107 SB-715992 (Ispinesib) Featured Ispinesib (SB 715992) is a potent mitotic kinesin KSP (Eg5) inhibitor with a Ki and an IC50 of 0.6 and 4.1 nM, respectively.
DC12378 Itacitinib(INCB039110) Featured Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.
DCAPI1510 Ixabepilone Featured Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors.
DC7175 JNJ-26854165 (Serdemetan) Featured JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.
DC7177 JNJ 38877605 Featured JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
DC9272 K 858 Featured K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics.
DC8247 KNK437 Featured KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>